<p>根據 Atlas Capital Advisors Inc.最近向證券交易委員會（SEC）提交的 13F 文件，該公司在 CVS Health Corporation（紐約證券交易所代碼：CVS - 免費報告）中的持股在第一季度增加了 1,463.2%。該機構投資者在此期間購買了額外的 15,817 股後，持有該藥房運營商的 16,898 股股票。根據其最近向證券交易委員會（SEC）提交的文件，Atlas Capital Advisors Inc.在 CVS Health 的持股價值為 1,145,000 美元。</p>
<ul>
<li>MarketBeat 週報 – 05/12 - 05/16</li>
</ul>
<p>其他一些對沖基金最近也買賣了該股票的股份。先鋒集團（Vanguard Group Inc.）在第一季度將其在 CVS Health 的股份增加了 0.8%。先鋒集團目前擁有 118,335,394 股該藥房運營商的股票，價值 8,017,223,000 美元，此前在上個季度又收購了 969,027 股。道奇與考克斯（Dodge &amp; Cox）在第四季度將其在 CVS Health 的股份增加了 11.2%。道奇與考克斯目前擁有 70,105,899 股該藥房運營商的股票，價值 3,147,054,000 美元，此前在上個季度又收購了 7,075,209 股。資本世界投資者（Capital World Investors）在第四季度將其在 CVS Health 的股份增加了 26.6%。資本世界投資者目前擁有 61,039,777 股該藥房運營商的股票，價值 2,739,927,000 美元，此前在上個季度又收購了 12,819,148 股。資本國際投資者（Capital International Investors）在第四季度將其在 CVS Health 的股份增加了 4.8%。資本國際投資者目前擁有 26,666,401 股該藥房運營商的股票，價值 1,196,989,000 美元，此前在上個季度又收購了 1,212,126 股。最後，查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第一季度將其在 CVS Health 的股份增加了 5.6%。查爾斯·施瓦布投資管理公司目前擁有 13,647,873 股該藥房運營商的股票，價值 924,643,000 美元，此前在上個季度又購買了 728,924 股。機構投資者和對沖基金持有該公司 80.66% 的股份。</p>
<h2>CVS Health 的內部交易</h2>
<p>在相關消息中，董事 Guy P. Sansone 於 6 月 5 日（星期四）購買了 1,570 股該公司的股票。該股票的平均購買成本為每股 63.70 美元，總價值為 100,009.00 美元。收購完成後，該董事直接持有公司 12,007 股，價值 764,845.90 美元。此次交易使其持股增加了 15.04%。該收購已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。公司內部人士持有該公司 1.22% 的股份。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>現在是購買諾和諾德股票的好時機嗎？</li>
</ul>
<p>一些研究公司最近對 CVS 發佈了報告。巴克萊（Barclays）在 8 月 1 日（星期五）的研究報告中將 CVS Health 的目標股價從 79.00 美元上調至 80.00 美元，並給予該股票 “超配” 評級。伯恩斯坦銀行（Bernstein Bank）在 7 月 16 日（星期三）的研究報告中將 CVS Health 的目標股價從 78.00 美元下調至 72.00 美元，並對該股票給予 “市場表現” 評級。傑富瑞金融集團（Jefferies Financial Group）在 6 月 30 日（星期一）的研究報告中將 CVS Health 的目標股價從 74.00 美元上調至 80.00 美元，並給予該股票 “買入” 評級。加拿大皇家銀行（Royal Bank Of Canada）在 5 月 5 日（星期一）的研究報告中將 CVS Health 的目標股價從 74.00 美元上調至 81.00 美元，並給予該股票 “跑贏大盤” 評級。最後，富國銀行（Wells Fargo &amp; Company）在 5 月 6 日（星期二）的研究報告中重申了 “超配” 評級，並將 CVS Health 的目標股價設定為 84.00 美元（之前為 76.00 美元）。三位股票研究分析師對該股票給予持有評級，十八位給予買入評級，一位給予強烈買入評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，共識目標股價為 75.11 美元。</p>
<p><strong>查看我們關於 CVS Health 的最新研究報告</strong></p>
<h2>CVS Health 股票表現</h2>
<ul>
<li>在業績疲軟和 CVS-諾和諾德合作後，艾利利（Eli Lilly）值得購買嗎？</li>
</ul>
<p>CVS 股票在星期五開盤價為 65.49 美元。該股票的 50 日移動平均價格為 64.68 美元，200 日移動平均價格為 64.23 美元。該股票的市值為 830.6 億美元，市盈率為 18.29，市盈增長比率為 0.70，貝塔值為 0.58。CVS Health Corporation 的 1 年最低價為 43.56 美元，1 年最高價為 72.51 美元。該公司的債務股本比率為 0.74，速動比率為 0.62，流動比率為 0.80。</p>
<p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最近於 7 月 31 日（星期四）發佈了季度財報。該藥房運營商報告本季度每股收益（EPS）為 1.81 美元，超出市場共識預期的 1.46 美元，超出 0.35 美元。該公司本季度的收入為 989.2 億美元，而分析師預期為 948.7 億美元。CVS Health 的股本回報率為 10.51%，淨利潤率為 1.17%。CVS Health 的收入同比增長 8.4%。在去年同期，該公司每股收益為 1.83 美元。賣方分析師預測 CVS Health Corporation 在本財年將發佈 5.89 美元的每股收益。</p>
<h2>CVS Health 股息公告</h2>
<p>該公司最近還披露了季度股息，該股息於 8 月 1 日（星期五）支付。7 月 22 日（星期二）的登記投資者獲得每股 0.665 美元的股息。該股息的除息日為 7 月 22 日（星期二）。這代表着每年 2.66 美元的股息和 4.1% 的收益率。CVS Health 的派息比率目前為 74.30%。</p>
<h2>CVS Health 簡介</h2>
<p>（免費報告）</p>
<p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房及消費者健康部門運營。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們認為比 CVS Health 更好的股票</li>
<li>市盈率計算：如何評估股票</li>
<li>MarketBeat 週迴顧 – 08/04 - 08/08</li>
<li>商業服務股票投資</li>
<li>Airbnb 超出預期盈利，但增長故事正在失去高度</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>Netflix 的多頭與空頭：誰將在這次回調中獲勝？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資$1,000 在 CVS Health 嗎？</h2>
<p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 CVS Health 並不在名單上。</p>
<p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西維斯

<p>Atlas Capital Advisors Inc. 在第一季度顯著增加了對 CVS Health Corporation 的持股，增幅達到 1,463.2%，目前持有 16,898 股，價值 1,145,000 美元。其他機構投資者，包括先鋒集團和道奇與考克斯，也提高了他們的持倉。CVS Health 的股票共識評級為 “適度買入”，目標價為 75.11 美元。該股票開盤價為 65.49 美元，市值為 830.6 億美元，市盈率為 18.29。過去一年中，CVS Health 的股票價格在 43.56 美元至 72.51 美元之間波動</p>

<p>Atlas Capital Advisors Inc. raised its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 1,463.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,898 shares of the pharmacy operator's stock after purchasing an additional 15,817 shares during the period. Atlas Capital Advisors Inc.'s holdings in CVS Health were worth $1,145,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根據 Atlas Capital Advisors Inc.最近向證券交易委員會（SEC）提交的 13F 文件，該公司在 CVS Health Corporation（紐約證券交易所代碼：CVS - 免費報告）中的持股在第一季度增加了 1,463.2%。該機構投資者在此期間購買了額外的 15,817 股後，持有該藥房運營商的 16,898 股股票。根據其最近向證券交易委員會（SEC）提交的文件，Atlas Capital Advisors Inc.在 CVS Health 的持股價值為 1,145,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 05/12 - 05/16</li>
</ul>
</div><p>A number of other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of CVS Health by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator's stock worth $8,017,223,000 after acquiring an additional 969,027 shares in the last quarter. Dodge &amp; Cox raised its position in shares of CVS Health by 11.2% during the 4th quarter. Dodge &amp; Cox now owns 70,105,899 shares of the pharmacy operator's stock worth $3,147,054,000 after acquiring an additional 7,075,209 shares in the last quarter. Capital World Investors raised its position in shares of CVS Health by 26.6% during the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock worth $2,739,927,000 after acquiring an additional 12,819,148 shares in the last quarter. Capital International Investors raised its position in shares of CVS Health by 4.8% during the 4th quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock worth $1,196,989,000 after acquiring an additional 1,212,126 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in CVS Health by 5.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator's stock worth $924,643,000 after buying an additional 728,924 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金最近也買賣了該股票的股份。先鋒集團（Vanguard Group Inc.）在第一季度將其在 CVS Health 的股份增加了 0.8%。先鋒集團目前擁有 118,335,394 股該藥房運營商的股票，價值 8,017,223,000 美元，此前在上個季度又收購了 969,027 股。道奇與考克斯（Dodge &amp; Cox）在第四季度將其在 CVS Health 的股份增加了 11.2%。道奇與考克斯目前擁有 70,105,899 股該藥房運營商的股票，價值 3,147,054,000 美元，此前在上個季度又收購了 7,075,209 股。資本世界投資者（Capital World Investors）在第四季度將其在 CVS Health 的股份增加了 26.6%。資本世界投資者目前擁有 61,039,777 股該藥房運營商的股票，價值 2,739,927,000 美元，此前在上個季度又收購了 12,819,148 股。資本國際投資者（Capital International Investors）在第四季度將其在 CVS Health 的股份增加了 4.8%。資本國際投資者目前擁有 26,666,401 股該藥房運營商的股票，價值 1,196,989,000 美元，此前在上個季度又收購了 1,212,126 股。最後，查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第一季度將其在 CVS Health 的股份增加了 5.6%。查爾斯·施瓦布投資管理公司目前擁有 13,647,873 股該藥房運營商的股票，價值 924,643,000 美元，此前在上個季度又購買了 728,924 股。機構投資者和對沖基金持有該公司 80.66% 的股份。</p>
</div><h2>Insider Transactions at CVS Health</h2>
<div class="lb-trans"><h2>CVS Health 的內部交易</h2>
</div><p>In related news, Director Guy P. Sansone purchased 1,570 shares of the business's stock in a transaction dated Thursday, June 5th. The stock was bought at an average cost of $63.70 per share, with a total value of $100,009.00. Following the completion of the acquisition, the director directly owned 12,007 shares in the company, valued at $764,845.90. The trade was a 15.04% increase in their position. The acquisition was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.22% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，董事 Guy P. Sansone 於 6 月 5 日（星期四）購買了 1,570 股該公司的股票。該股票的平均購買成本為每股 63.70 美元，總價值為 100,009.00 美元。收購完成後，該董事直接持有公司 12,007 股，價值 764,845.90 美元。此次交易使其持股增加了 15.04%。該收購已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。公司內部人士持有該公司 1.22% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>現在是購買諾和諾德股票的好時機嗎？</li>
</ul>
</div><p>A number of research firms recently issued reports on CVS. Barclays raised their price target on CVS Health from $79.00 to $80.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, August 1st. Bernstein Bank dropped their price target on CVS Health from $78.00 to $72.00 and set a &#34;market perform&#34; rating on the stock in a research note on Wednesday, July 16th. Jefferies Financial Group raised their price target on CVS Health from $74.00 to $80.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, June 30th. Royal Bank Of Canada raised their price target on CVS Health from $74.00 to $81.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, May 5th. Finally, Wells Fargo &amp; Company restated an &#34;overweight&#34; rating and set a $84.00 price target (up previously from $76.00) on shares of CVS Health in a research note on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $75.11.</p>
<div class="lb-trans"><p>一些研究公司最近對 CVS 發佈了報告。巴克萊（Barclays）在 8 月 1 日（星期五）的研究報告中將 CVS Health 的目標股價從 79.00 美元上調至 80.00 美元，並給予該股票 “超配” 評級。伯恩斯坦銀行（Bernstein Bank）在 7 月 16 日（星期三）的研究報告中將 CVS Health 的目標股價從 78.00 美元下調至 72.00 美元，並對該股票給予 “市場表現” 評級。傑富瑞金融集團（Jefferies Financial Group）在 6 月 30 日（星期一）的研究報告中將 CVS Health 的目標股價從 74.00 美元上調至 80.00 美元，並給予該股票 “買入” 評級。加拿大皇家銀行（Royal Bank Of Canada）在 5 月 5 日（星期一）的研究報告中將 CVS Health 的目標股價從 74.00 美元上調至 81.00 美元，並給予該股票 “跑贏大盤” 評級。最後，富國銀行（Wells Fargo &amp; Company）在 5 月 6 日（星期二）的研究報告中重申了 “超配” 評級，並將 CVS Health 的目標股價設定為 84.00 美元（之前為 76.00 美元）。三位股票研究分析師對該股票給予持有評級，十八位給予買入評級，一位給予強烈買入評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，共識目標股價為 75.11 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on CVS Health</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CVS Health 的最新研究報告</strong></p>
</div><h2>CVS Health Stock Performance</h2>
<div class="lb-trans"><h2>CVS Health 股票表現</h2>
</div><ul>
<li>Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?</li>
</ul>
<div class="lb-trans"><ul>
<li>在業績疲軟和 CVS-諾和諾德合作後，艾利利（Eli Lilly）值得購買嗎？</li>
</ul>
</div><p>Shares of CVS stock opened at $65.49 on Friday. The stock has a fifty day moving average price of $64.68 and a 200 day moving average price of $64.23. The stock has a market cap of $83.06 billion, a PE ratio of 18.29, a P/E/G ratio of 0.70 and a beta of 0.58. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $72.51. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80.</p>
<div class="lb-trans"><p>CVS 股票在星期五開盤價為 65.49 美元。該股票的 50 日移動平均價格為 64.68 美元，200 日移動平均價格為 64.23 美元。該股票的市值為 830.6 億美元，市盈率為 18.29，市盈增長比率為 0.70，貝塔值為 0.58。CVS Health Corporation 的 1 年最低價為 43.56 美元，1 年最高價為 72.51 美元。該公司的債務股本比率為 0.74，速動比率為 0.62，流動比率為 0.80。</p>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. The firm had revenue of $98.92 billion during the quarter, compared to analysts' expectations of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%. CVS Health's revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.83 earnings per share. Sell-side analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最近於 7 月 31 日（星期四）發佈了季度財報。該藥房運營商報告本季度每股收益（EPS）為 1.81 美元，超出市場共識預期的 1.46 美元，超出 0.35 美元。該公司本季度的收入為 989.2 億美元，而分析師預期為 948.7 億美元。CVS Health 的股本回報率為 10.51%，淨利潤率為 1.17%。CVS Health 的收入同比增長 8.4%。在去年同期，該公司每股收益為 1.83 美元。賣方分析師預測 CVS Health Corporation 在本財年將發佈 5.89 美元的每股收益。</p>
</div><h2>CVS Health Dividend Announcement</h2>
<div class="lb-trans"><h2>CVS Health 股息公告</h2>
</div><p>The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Tuesday, July 22nd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, July 22nd. This represents a $2.66 annualized dividend and a yield of 4.1%. CVS Health's payout ratio is currently 74.30%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，該股息於 8 月 1 日（星期五）支付。7 月 22 日（星期二）的登記投資者獲得每股 0.665 美元的股息。該股息的除息日為 7 月 22 日（星期二）。這代表着每年 2.66 美元的股息和 4.1% 的收益率。CVS Health 的派息比率目前為 74.30%。</p>
</div><h2>CVS Health Profile</h2>
<div class="lb-trans"><h2>CVS Health 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p>
<div class="lb-trans"><p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房及消費者健康部門運營。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>MarketBeat Week in Review – 08/04 - 08/08</li>
<li>Business Services Stocks Investing</li>
<li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 CVS Health 更好的股票</li>
<li>市盈率計算：如何評估股票</li>
<li>MarketBeat 週迴顧 – 08/04 - 08/08</li>
<li>商業服務股票投資</li>
<li>Airbnb 超出預期盈利，但增長故事正在失去高度</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>Netflix 的多頭與空頭：誰將在這次回調中獲勝？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 CVS Health 嗎？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 CVS Health 並不在名單上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Atlas Capital Advisors Inc. 購入了西維斯健康公司（NYSE:CVS）的股票